Malaysia Antibacterial (Antibiotics) Drugs Market Analysis Report 2022 to 2030

Malaysia Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

Malaysia Antibacterial (Antibiotics) Drugs Market is at around $81.45 Mn in 2023 and is projected to reach $110.11 Mn in 2030, exhibiting a CAGR of 4.4% during the forecast period. The market is driven by rising rates of infectious diseases, expanding healthcare infrastructure and awareness, and technological advancements. The market is dominated by key players like Duopharma Biotech Bhd, Pharmaniaga Bhd, Ltd., Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.

ID: IN10MYPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Aneri Parekh

Buy Now

Malaysia Antibacterial (Antibiotics) Drugs Market Executive Summary

Malaysia Antibacterial (Antibiotics) Drugs Market is at around $81.45 Mn in 2023 and is projected to reach $110.11 Mn in 2030, exhibiting a CAGR of 4.4% during the forecast period.

Pharmaceutical companies, healthcare providers, and regulatory agencies oversee the acquisition, administration, and surveillance of antibiotics within the Malaysian antibiotics industry. The market is affected by several factors, such as the frequency of bacterial illnesses, the healthcare system, governmental regulations, and trends in antibiotic resistance. Stakeholders must comprehend market dynamics to effectively address public health concerns and ensure antibiotic stewardship.

The rising rate of bacterial infections and rising healthcare costs are driving the continuous growth of the antibiotics market in Malaysia. To meet the increasing demand, major firms are concentrating on broadening their product offerings and improving their distribution systems. The growth of healthcare infrastructure through government initiatives and the growing knowledge of antibiotic resistance are also influencing market dynamics.

There has been an apparent shift in the antibiotic sector in recent years. In 2023, the market was valued at $50.91 Bn, and further growth is expected to continue. The main reasons for this increase are new product developments and infectious diseases. The necessity for additional research and development, innovative antimicrobial formulations, and antibiotic prescriptions has also contributed to these advancements. New antimicrobial discoveries and urbanization influence market expansion.

One of Malaysia's top pharmaceutical companies, Duopharma Biotech Berhad (DBB), is well-known in the antibiotics industry. Approximately 20% of the generics market is accounted for by them, with antibiotics being a major product category. Generic antibiotics from DBB include fluoroquinolones, macrolides, cephalosporins, and penicillins. Additionally, their line of branded antibiotics, which includes Omesec and Prelica, is expanding. Additionally, they export antibiotics to more than 20 nations, such as Bangladesh, Ethiopia, and Vietnam.

Malaysia antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Infectious Diseases: Malaysia's expanding bacterial and infectious disease prevalence fuels the antibiotics industry.

Growing Awareness and Healthcare Infrastructure: Improved healthcare infrastructure and the population's awareness about antibiotics' role in treating bacterial infections fuel market growth.

Technology Advancements: New antimicrobial drug delivery technologies and formulations boost market growth. Innovative technology helps identify novel antibiotics and improve their efficacy.

Market Restraints:

Regulatory Issues: Antibiotics' strict manufacturing and product registration requirements might slow market growth.

Economic Factors: Economic downturns can affect healthcare spending and antibiotic affordability for patients and providers, affecting market growth.

Alternative Treatment Competition: Awareness of antibiotics' negative effects on gut microbiota and immune function may increase demand for probiotics or herbal therapies, reducing antibiotic use.

Healthcare Policies and Regulatory Landscape

The Drug Control Authority (DCA) oversees the registration procedure for innovative pharmaceuticals and biologics in Malaysia, as per the Control of Pharmaceuticals and Cosmetics Regulations 1984. Applications must be made online using QUEST3. Product registration applications can be made safely via QUEST online membership registration. DCA requires high-quality data and strict protocol adherence to comply with international Good Clinical Practice and Good Manufacturing Practice standards like those set by the International Council on Harmonization (ICH), which can add complexity and delay. Malaysia has several ethnic groups, therefore pharmaceutical safety and efficacy must be assessed across populations. More clinical studies or data analysis may increase costs and complicate problems.

Competitive Landscape

Key Players:

Duopharma Biotech Bhd
Pharmaniaga Bhd
Pfizer Inc.
Roche
Novartis AG
GlaxoSmithKline plc
Abbott Laboratories
Johnson & Johnson
Merck & Co., Inc.
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.